首页> 外文期刊>European journal of nuclear medicine >The use of 99mTc-phytate for sentinel node mapping in melanoma, breast cancer and vulvar cancer: a study of 100 cases.
【24h】

The use of 99mTc-phytate for sentinel node mapping in melanoma, breast cancer and vulvar cancer: a study of 100 cases.

机译:99mTc-植酸盐在黑素瘤,乳腺癌和外阴癌前哨淋巴结定位中的应用:一项针对100例患者的研究。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Sentinel node mapping reduces surgical morbidity and allows the use of more accurate tumour staging techniques. Radionuclide studies are preferentially performed using small colloids, which have limited availability in our country. The possibility of using phytate for sentinel node mapping was raised because of the similarity between its biodistribution and that of nanocolloids in the reticulo-endothelial system. In this paper we evaluated the use of 99mTc-phytate for sentinel node mapping, correlating the histopathological results with the status of the rest of the lymph node chain in different malignant tumours. A total of 100 patients were studied. group 1 consisted of 62 patients with breast cancer, group 2 of 20 patients with melanoma and group 3 of 18 patients with vulvar carcinoma. Lymph node scintigraphy was carried out after injecting 99mTc-phytate subdermally, and the sentinel node projection was marked on the skin. After 18-24 h, intraoperative sentinel node localisation was performed using a gamma probe (combined with visual localisation using patent blue dye) in 75 patients, and lymph node dissection was then carried out. Radionuclide scintigraphy identified the sentinel node in 98% of all studies. Intraoperative detection using the gamma probe was equally efficient: group 1=93% (38/41), group 2=95% (18/19) and group 3=100% (15/15). The sentinel node was involved in 41%, 31% and 20% of cases in groups 1, 2 and 3, respectively. Among the patients with positive nodes, the sentinel node was the only one affected in 53% of group 1, 50% of group 2 and 67% of group 3 cases. The method's negative predictive value was 91% in group 1 and 100% in the other groups. One false-negative study occurred in a patient who had a multifocal tumour and an intraparenchymatous lymph node; another occurred in a patient with a macroscopically affected node found during surgery. There were no side-effects related to the 99mTc-phytate. It is concluded that scintigraphic and intraoperative sentinel node identification was satisfactorily performed using 99mTc-phytate. The results were comparable to those previously described in the literature using other radiopharmaceuticals. Easy availability and low cost justify the use of phytate in our practice.
机译:前哨淋巴结定位术降低了手术发病率,并允许使用更准确的肿瘤分期技术。放射性核素的研究优先使用小胶体,而在我国,胶体的可用性有限。由于肌醇六磷酸的生物分布与网状内皮系统中纳米胶体的生物分布相似,因此增加了使用肌醇六磷酸进行前哨淋巴结定位的可能性。在本文中,我们评估了99mTc-植酸盐在前哨淋巴结定位中的应用,将组织病理学结果与不同恶性肿瘤中其余淋巴结链的状态相关联。共研究了100名患者。第一组由62例乳腺癌患者组成,第二组由20例黑色素瘤患者组成,第三组由18例外阴癌患者组成。皮下注射99mTc-植酸盐后进行淋巴结闪烁显像,并在皮肤上标记前哨淋巴结突出。 18-24小时后,对75例患者进行了术中前哨淋巴结定位(使用伽玛探针结合视觉定位)。放射性核素闪烁显像术在所有研究中识别出前哨淋巴结98%。使用伽玛探针进行术中检测同样有效:第1组= 93%(38/41),第2组= 95%(18/19),第3组= 100%(15/15)。第1、2和3组分别有41%,31%和20%的病例涉及前哨淋巴结。在淋巴结阳性的患者中,前哨淋巴结是第1组的53%的患者中唯一受累的患者,第2组的50%和第3组的67%。该方法的阴性预测值在第1组中为91%,在其他组中为100%。一项假阴性研究发生在患有多灶性肿瘤和实质内淋巴结的患者中。另一例发生在手术过程中发现淋巴结受到宏观影响的患者中。没有与99mTc植酸盐有关的副作用。结论是使用99mTc-植酸盐可令人满意地进行闪烁显像和术中前哨淋巴结识别。结果与先前使用其他放射性药物在文献中描述的结果相当。易获得性和低成本证明了在我们的实践中使用肌醇六磷酸是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号